

Special Issue

Current Clinical Studies of Pancreatic Ductal Adenocarcinoma

Message from the Guest Editor

We would like to announce the launch of a Special Issue on 'Current Clinical Studies of Pancreatic Ductal Adenocarcinoma' which will take the form of a multi-disciplinary project, incorporating research on medical oncology, current trends in neoadjuvant and adjuvant chemotherapy for pancreatic cancer, and surgical managements such as open and minimally invasive techniques. This Special Issue will also highlight studies on the locoregional treatment space including advances in SBRT and MR-guided Linac along with irreversible electroporation (IRE) using an open surgical approach and a percutaneous approach. Additionally, bench research analyzing the role of local treatment in enhancing immune response and/or the impact of local treatment on the stromal tissue of pancreatic cancer, which improves the uptake of immunotherapy, will also be incorporated.

Guest Editor

Dr. Govindarajan Narayanan

1. Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
2. Miami Cardiac and Vascular, Baptist Health South Florida, Miami, FL 33176, USA
3. Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA

Deadline for manuscript submissions

closed (20 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/182691

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)